ProQR Therapeutics (NASDAQ:PRQR) Upgraded to “Hold” by BidaskClub

ProQR Therapeutics (NASDAQ:PRQR) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a report released on Wednesday, BidAskClub reports.

A number of other equities analysts have also issued reports on the stock. Citigroup boosted their target price on shares of ProQR Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Zacks Investment Research raised shares of ProQR Therapeutics from a “hold” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Wednesday, August 14th. ValuEngine upgraded shares of ProQR Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 28th. Finally, Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of ProQR Therapeutics in a report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $27.00.

Shares of PRQR traded down $0.09 during mid-day trading on Wednesday, hitting $9.63. The company’s stock had a trading volume of 2,304 shares, compared to its average volume of 349,853. The stock’s 50-day moving average is $7.75 and its two-hundred day moving average is $8.32. The firm has a market capitalization of $432.95 million, a PE ratio of -7.40 and a beta of 0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.01 and a current ratio of 7.01. ProQR Therapeutics has a one year low of $5.49 and a one year high of $18.94.

Several hedge funds have recently made changes to their positions in PRQR. Millennium Management LLC grew its holdings in shares of ProQR Therapeutics by 223.5% during the 3rd quarter. Millennium Management LLC now owns 222,579 shares of the biopharmaceutical company’s stock worth $1,282,000 after purchasing an additional 402,779 shares in the last quarter. State Street Corp increased its holdings in ProQR Therapeutics by 13.4% in the 3rd quarter. State Street Corp now owns 123,870 shares of the biopharmaceutical company’s stock valued at $713,000 after buying an additional 14,610 shares during the period. International Biotechnology Trust PLC bought a new stake in ProQR Therapeutics in the 2nd quarter valued at $511,000. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $92,000. Finally, Tower Research Capital LLC TRC acquired a new position in shares of ProQR Therapeutics in the 2nd quarter valued at $79,000. Institutional investors own 43.89% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Featured Article: How can you know how many shares are floating?

Analyst Recommendations for ProQR Therapeutics (NASDAQ:PRQR)

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit